Long acting gnrha

Long-acting GnRHa (0.93–1.25 mg intramuscular [i.m.] once; IPSEN, Paris, France) or a short-acting GnRHa (0.1 mg i.m. per day until HCG day; IPSEN) was usually administered on the 18th to 22nd days of menstrual cycle (5–7 days after ovulation) after the corpus luteum detected on the vaginal ultrasound, if necessary, we measured serum progesterone level to determine the ovulation. Two to 3 weeks later, the vaginal ultrasound and blood hormones test (FSH, luteinizing hormone [LH], estradiol [E₂]) were necessary. Gonadotropin 100 to 300 U/day can be administered when the results fully reached the pituitary complete down-regulation criteria. Every 3 to 5 days, the ultrasound and blood hormones were monitored to evaluate follicular development, when at least one follicle ≥18 mm or 3 follicles ≥17 mm in diameter emerges, HCG (Livon, China) 4000 to 10,000 U or GnRHa (IPSEN) 0.2 mg can be used as a trigger. Thirty-six to 38 h later, the vaginal oocyte retrieval was performed, embryos were cultured until the 3rd to 5th day, and then the embryo transfer was performed. Corpus luteal support began from the oocyte recovery with a progesterone intramuscular injection 60 mg/day or progesterone capsules 600 mg/day trans-vaginal until the day of pregnancy test.